The data suggested that BXT could decrease the infarction size, myeloperoxidase, interleukin-6 (IL-6), and levels of C-reactive protein (CRP) and enhance SOD activities and anti-inflammatory media such as interleukin-10 (IL-10). This evidence concerns the gene CRP and infarction.